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Butyrate, a short-chain fatty acid produced in the colon, induces cell cycle arrest, differentiation, and apoptosis in transformed
cell lines. In this report, we study the effects of butyrate (BuA) on the growth of Ehrlich ascites tumor (EAT) cells in vivo. BuA,
when injected intraperitoneally (i.p) into mice, inhibited proliferation of EAT cells. Further, induction of apoptosis in EAT cells
was monitored by nuclear condensation, annexin-V staining, DNA fragmentation, and translocation of caspase-activated DNase
into nucleus upon BuA-treatment. Ac-DEVD-CHO, a caspase-3 inhibitor, completely inhibited BuA-induced apoptosis, indicating
that activation of caspase-3 mediates the apoptotic pathway in EAT cells. The proapoptotic effect of BuA also reflects on the anti-
angiogenic pathway in EAT cells. The antiangiogenic effect of BuA in vivo was demonstrated by the downregulation of the secretion
of VEGF in EAT cells. CD31 immunohistochemical staining of peritoneum sections clearly indicated a potential angioinhibitory
effect of BuA in EAT cells. These results suggest that BuA, besides regulating other fundamental cellular processes, is able to mod-
ulate the expression/secretion of the key angiogenic growth factor VEGF in EAT cells.
 2005 Elsevier Inc. All rights reserved.
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vessels from preexisting vasculature, is now being
widely recognized for its role in tumor progression
and metastasis [1]. Angiogenesis is a multistep process
that includes endothelial cell proliferation, migration,
and basement membrane degradation [1,2]. With the
discovery of the role of angiogenesis in tumor growth
and progression, considerable efforts have been direct-
ed towards antiangiogenic therapy as a new modality
to treat human cancers. In recent years, attention
has been given to identifying non-toxic, endothelial
cell specific, diet-derived compounds as antiangiogenic
agents for cancer therapy, in an effort to reduce the
toxic side effects [3–6].
The vascular endothelial growth factor (VEGF) has
been considered a key cytokine and is expressed in many0006-291X/$ - see front matter  2005 Elsevier Inc. All rights reserved.
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E-mail address: belakama@umdnj.edu (M. Belakavadi).types of human malignancies including breast and ovar-
ian cancers [7,8]. High levels of VEGF have been found
in a variety of effusions accompanying pathologic disor-
ders like edema formation in the brain, human rheuma-
toid synovial fluid, and malignant ascites [9].
Consequently, inhibition of fluid accumulation and tu-
mor growth by neutralization of VEGF has been dem-
onstrated, underlining the importance of VEGF in
malignant ascites formation [10,11]. Two high affinity
receptor tyrosine kinases for VEGF, VEGFR-1/Flt-1,
and VEGFR-2/KDR/Flk-1, have been identified in
endothelium [12]. Interaction of VEGF with Flk-1 is a
requirement for malignant ascites formation [9]. Inter-
ference with the angiogenic ligand, VEGF, or its recep-
tors, Flt-1 and KDR, offers a potential therapeutic
window for treatment of malignant ascites formation
and tumor growth.
Sodium butyrate, a short-chain fatty acid (SCFA)
produced during the fermentation of dietary fiber by
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uated as an anti-neoplastic therapeutic agent [13], and
clinical trials of BuA and its derivatives in cancer pa-
tients have already been initiated [14,15]. The inhibito-
ry role of BuA against tumor growth is mediated
through a direct effect on tumor cells that results in
cell cycle arrest, differentiation, or apoptosis [16–19].
BuA-induced apoptosis has been shown to involve
activated caspase-3 in several cell lines [20,21]. In
addition, BuA has also been shown to activate p21,
a cyclin-dependent kinase inhibitor, independent of
p53 activation to induce cell death [22–25]. In molec-
ular terms, the action of BuA is probably related to
histone deacetylase inhibition, leading to hyperacetyla-
tion of chromatin components, such as histones and
non-histone proteins, which leads to altered gene
expression [26].
In addition, BuA has been shown to modulate the
activity of the transcription factor NF-jB in a number
of different cell types, including colon cancer cells [27].
The ability of BuA to modulate NF-jB activity may
arise from its ability to inhibit histone deacetylases.
The antiproliferative effect of BuA on transformed
cells is well established, and it has emerged as an anti-
angiogenic agent by directly repressing the expression
of angiogenic ligands or indirectly interfering with
endothelial cell proliferation/enzymes required for
angiogenesis [28–30]. We have previously shown that
BuA could repress gene expression of VEGF/KDR
systems in Ehrlich ascites tumor (EAT) cells in vitro
[31]. Recently, it has been shown that BuA inhibits
the translocation of HIF-1a, a key regulator of
VEGF, thereby inhibiting angiogenesis [32]. The
molecular mechanisms involved in modulation of both
apoptotic as well as antiangiogenic cascades in EAT
cells (in vivo) have not been defined so far. The aim
of this study was to better understand the downstream
targets for BuA-induced apoptotic and/or antiangio-
genic pathways during the growth of EAT cells. Here,
we provide evidence that BuA induces apoptosis in
EAT cells with typical features such as apoptotic
bodies, DNA fragmentation, activation of caspase-ac-
tivated DNase (CAD) and also, in parallel exerts anti-
angiogenic effects characterized by downregulation of
VEGF production and endothelial cell proliferation
in vivo.Materials and methods
RNase, iodoacetate, ethidium bromide, annexin-V kit, and anti-
bodies against CD31 were from Sigma–Aldrich, USA. Caspase-3
inhibitor Ac-DEVD-CHO, antibodies against DFF-40 (CAD), NF-jB
(FITC tagged), and ABC-reagent for CD31 staining were procured
from Santa Cruz Biotechnology, CA, USA. Secondary antibodies and
BCIP/NBT substrate were procured from Bangalore Genei, India. All
other chemicals and reagents were of analytical grade.EAT cell growth in vivo and butyrate treatment. EAT cells (5 · 106
cells/mouse) were injected intraperitoneally (i.p) into 8-week-old Swiss
albino mice and the weights of the animals were monitored every day.
Six days after tumor inoculation, 100 lM (300 ll/mouse) BuA was
injected intraperitoneally into the EAT bearing mice every alternate day
and the mice were sacrificed on the 12th day. For ELISA studies, the
animals were treated from the day 2nd to 12th day of growth period.
Cell number and ascites volume. Untreated or BuA-treated EAT
bearing mice were sacrificed, and small incisions were made in the
abdominal region. EAT cells along with the ascites fluid were har-
vested into a beaker containing 2 ml saline and centrifuged at 3000 rpm
for 10 min at 4 C. Subtracting the volume of saline added previously
from the volume of the supernatant gave the volume of ascites fluid.
After harvesting, the EAT cells were resuspended in HBSS and
counted in a hemocytometer.
Ethidium bromide/acridine orange and annexin-V staining. Nuclear
staining was performed according to the method of Srinivas et al. [33].
EAT cells either untreated or treated with BuA (10 mM in vitro or
300 ll of 100 lM in vivo) for 2 h in complete HBSS were smeared on a
glass slide, fixed with methanol/acetic acid (3:1), and air-dried in a
humidified chamber. The cells were hydrated with PBS and stained
with a mixture (1:1) of ethidium bromide/acridine orange (10 lg/ml)
solutions. The cells were immediately washed with PBS thrice and
viewed under Leitz-DIAPLAN fluorescent microscope.
For annexin-V staining, the cells were treated as described above.
In brief, EAT cells were washed with binding buffer (10 mMHepes, pH
7.5, containing 140 mM NaCl and 2.5 mM CaCl2) and stained with
annexin-V detection kit (APO-AC) as per the protocol supplied by the
manufacturer. After 10 min, cells were washed thrice with binding
buffer and the greenish red apoptotic cells were observed using Leitz-
DIAPLAN fluorescent microscope and photographed.
DNA isolation. EAT cells were either untreated or pretreated with
Ac-DEVD-CHO (100 lM) for 30 min at 37 C before being treated
with BuA for 2 h. The reactions were terminated using ice-cold HBSS
and the supernatant was removed by centrifugation. Cells were lysed in
a buffer containing 50 mM Tris–HCl, pH 8.0, and 0.5% SDS, and
incubated for 30 min at 37 C. The cell lysate was subjected to 8 M
potassium acetate precipitation and left for 1 h at 4 C. The superna-
tant was subjected to phenol/chloroform/isoamyl alcohol (25:24:1)
extraction, followed by chloroform extraction. DNA was precipitated
by adding 1:2 volumes of ice-cold ethanol. The precipitated DNA was
dissolved in 50 ll TE buffer (pH 8.0). The DNA was digested with
20 lg/ml RNase at 37 C for 1 h. The DNA was quantitated and re-
solved on 1.5% agarose gel, viewed under UV light, and documented
using Uvp-BioDoc-ItTM system.
Endonuclease activity. Endonuclease activity was performed
according to the method of Stein and Hansen [34] with little modifi-
cation. In brief, cytosolic extracts were prepared from EAT cells either
untreated or treated with BuA for 2 h in complete HBSS. After ter-
minating the reaction with ice-cold HBSS, cells were homogenized in a
glass–glass homogenizer in buffer A (10 mM Tris–HCl, pH 8.0,
0.1 mM EGTA, and 0.1% b-mercaptoethanol containing cocktail
proteolytic inhibitors). Cell debris was removed by low-speed centri-
fugation and the remaining supernatant was centrifuged at 17,000 rpm
for 1 h at 4 C to obtain a cytosolic fraction. 1% agarose was prepared,
and 10 lg/ml ethidium bromide and 50 lg/ml heat denatured salmon-
sperm DNA were added. It was then poured onto the glass petri dishes
and allowed to solidify at room temperature. Wells were prepared by
suction pressure and equal amounts of proteins were loaded onto each
well, incubated for 12–18 h at 37 C in a humidified chamber, and
visualized under UV-transilluminator, and the lysis zone was observed
around the well. The lysis of DNA in the agarose is directly propor-
tional to activity of the endonuclease.
Western blot analysis of CAD. Twenty micrograms of nuclear ex-
tracts prepared from the cells either untreated or treated with BuA for
2 h was separated on 10% SDS–PAGE and transferred to a nitrocel-
lulose membrane. After blocking with 5% BSA in Tris-buffered saline,
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for 2 h. The blot was washed thrice with TBST on a shaker and
incubated with secondary antibody tagged to alkaline phosphatase for
1 h. The blot was washed thrice with TBST for 10 min and the CAD
protein was detected by using chromogenic substrate BCIP/NBT.
VEGF-ELISA. VEGF-ELISA was carried out using the ascites of
EAT bearing mice treated with or without BuA in vivo. In brief, 100 ll
of ascites from control EAT bearing mice or the BuA-treated mice was
coated in a coating buffer at 4 C overnight. Subsequently, wells were
incubated with anti-VEGF165 antibodies, followed by incubation with
secondary antibodies tagged to alkaline phosphatase. BCIP/NBT was
used as a substrate.
Immunohistochemistry. Excised peritoneum from the mice was ei-
ther untreated or treated with BuA, was paraffin-blocked, and 5-lm
sections were prepared. The sections were fixed and immunostained for
CD31 as per the protocol supplied by the manufacturer (Santa Cruz
Biotechnology, CA, USA). In brief, sections were deparaffinized by
using xylene and hydrated with 100% ethanol for 5 min, followed by
95% for 2 min 80% for 2 min. Subsequently, the sections were incubated
with 3% H2O2 in PBS to block endogenous peroxidase activity. After
2 min, the sections were rinsed with PBS for 2 min, baked at 450 Hz for
10 min to retrieve the antigen, and hydrated with PBS for 2 min. Sec-
tions were incubated with anti-CD31 (PECAM-1) antibodies overnight
at 4 C. After tapping off the antibody, the slides were dipped for 5 min
in PBS. The sections were incubated with secondary antibody with
biotinylated rabbit anti-mouse IgG for 30 min at room temperature.
The slides were washed in PBS for 5 min and incubated with ABC-re-
agent for 45 min. After incubation, the slides were washed with histo-
buffer and incubated for 10 min with the substrate, DAB peroxidase.
Subsequently, the sections were counterstained with 2% hematoxylin
solution for 5 min and washed in tap water thrice for 5 min each. The
slides were processed and mounted using Entellan mountant solution.7th day 9th day 11th day
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ig. 1. (A,B) Effect of BuA on proliferation of EAT cells and ascites
ormation in vivo. EAT cells (5 · 106 cells/mouse, i.p) were injected
to albino mice and the weights of the mice were recorded to monitor
umor growth. Every alternate day (after the 6th day of tumor
oculation) BuA was injected (100 lM, 300 ll/mouse) into the mice
eritoneum. At least five mice were used for each experiment and the
esults obtained are averages of three individual experiments. Tumor-
earing mice treated with vehicle or BuA were sacrificed on 12th day.
AT cells and with ascites fluid were harvested. The total number of
ells (A) and the ascites volume (B) were recorded per mouse.Results
Antiproliferative effects of BuA on EAT cells and
decreased ascites secretion in vivo
Initially, an attempt was made to understand the in vi-
vo effect of BuA on the proliferation of EAT cells. Swiss
albino mice were treated with various concentrations of
BuA (0.01–10 mM). It was found that 100 lM (300 ll/
mouse) BuA significantly showed an antiproliferative ef-
fect towards EAT cells in vivo. Upon BuA-treatment,
the weight of the animals gradually decreased and the
survival time of the EAT bearing mice also increased
(data not shown). In contrast, the weights of untreated
EAT bearing mice steadily increased and they died in
normal growth period of about 12–13th day. The total
number of cells in untreated mice was 13.7 · 108 whereas
in BuA-treated mice there was 4.4 · 108 as shown in
Fig. 1A. The significant reduction in EAT cell number
in BuA-treated mice could also reflect the decreased
secretion of ascites by EAT cells. The characteristic fea-
ture of EAT is that it is an ascites tumor, and in re-
sponse to BuA-treatment, approximately 50%
reduction in ascites secretion was observed (Fig. 1B).
These preliminary data suggest that BuA acts as an anti-
proliferative agent in an EAT cell model system, and
more importantly BuA inhibits ascites secretion in vivo.F
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cBuA induces apoptosis in EAT cells
Several studies have reported that BuA induces apop-
tosis in a variety of cell types [20–25]. Hence, an attempt
wasmade to identifywhether theBuA-induced antiprolif-
erative effect on EAT cells was due to induction of apop-
tosis. Ethidium bromide/acridine orange staining of EAT
cells indicated the formation of condensed nuclei. As
shown in Fig. 2A, upon BuA-treatment, most cells under-
go apoptosis and showed distinct nuclear condensation as
Fig. 2. Ethidium bromide/acridine orange and annexin-V staining of EAT cells. (A) EAT cells were resuspended in complete HBSS and treated with
or without butyrate (10 mM, in vitro) for 2 h at 37 C. After incubation, cells were fixed with methanol/acetic acid (3:1) on glass slides and stained
with ethidium bromide/acridine orange (1:1, 10 lg/ml). Cells were washed extensively with PBS and viewed with a fluorescent microscope. (B) EAT
cells were treated with BuA as mentioned above and stained using an annexin-V apoptosis detection kit as per the manufacturers protocol.
996 M. Belakavadi et al. / Biochemical and Biophysical Research Communications 335 (2005) 993–1001compared to control cells which showed intact nuclear
architecture. In addition, in vivo BuA-treated cells were
also analyzed for nuclear condensation and showed a sim-
ilar pattern as observed in in vitro BuA-treated EAT cells
(data not shown).
In order to confirm that apoptosis was induced byBuA
in EAT cells, we stained the cells with annexin-V. It is evi-
dent fromFig. 2B that externalizationof phosphatidylser-
ine occurred on the membrane upon BuA-treatment. In
contrast, the untreated cells did not exhibit the external-
ization of phosphatidylserine on the membrane. The
greenish red (arrows indicated) stained cells clearly con-
firmed the flipping of phosphatidylserine on the mem-
brane, which is normally located inside the membrane.
The externalization of phosphatidylserine could be iden-
tified in apoptotic signaling pathways, and BuA clearly
showed flipping of phosphatidylserine in EAT cells, indi-
cating the apoptotic pathway in EAT cells.
BuA induces activation of caspase-3, CAD, and
endonuclease-II in EAT cells
After confirming that BuA induces EAT cell apopto-
sis, we next attempted to identify the mechanism of EATcell death. It is well recognized that various caspases
play a crucial role in apoptosis. We examined whether
or not BuA has any effect on the activation of cas-
pase-3, a cysteine protease responsible for morphologi-
cal changes and DNA degradation in apoptotic cells
[20,21]. Preincubation of EAT cells with caspase-3 inhib-
itor completely inhibited BuA induced nuclear conden-
sation (data not shown) and DNA degradation
(Fig. 3A). Since BuA-induced activation of caspase-3
in EAT cells, we further verified the activation of
CAD, which mediates genomic DNA degradation into
nucleosomal fragmentation. Fig. 3B compares the
Western blot analysis of CAD in both control and
BuA-treated EAT cells. It is evident that control nuclear
extract did not show the presence of CAD due to the
fact that CAD is associated with its inhibitor ICAD in
the cytosol [40]. Upon BuA-treatment, CAD (40 kDa)
dissociated from ICAD and translocated into nucleus
to fragment the genomic DNA. Consistent with the acti-
vation of caspase-3 protease in EAT cells, CAD, a
downstream endonuclease, is concomitantly activated
upon BuA-treatment.
Several studies have shown that activation of endo-
nuclease II is critical for DNA fragmentation and
Fig. 3. Analysis of apoptotic markers in EAT cells upon BuA-treatment. (A) Effect of BuA on genomic DNA: EAT cells were either untreated or
treated with BuA in complete HBSS for 2 h, and DNA was isolated by standard phenol/chloroform method. In parallel, cells were also preincubated
with the caspase-3 inhibitor Ac-DEVD-CHO for 30 min (100 lM) before being treated with BuA for 2 h and processed for DNA isolation. Ten
micrograms of DNA from control as well as BuA-treated EAT cells was resolved in 1.5% agarose gel and observed using a UV-transilluminator and
photographed (lane 1, control; lane 2, BuA-treated; lane 3, Ac-DEVD-CHO + BuA). (B) Activation of CAD upon BuA-treatment: 20 lg of nuclear
extract from cells either untreated or treated with BuA for 2 h was resolved by SDS–PAGE. Western blot analysis was performed using anti-CAD
antibodies. Lane 1, untreated nuclear extract; lane 2, BuA-treated nuclear extract. (C) Induction of endonuclease upon BuA-treatment: cytosolic
extracts were prepared from cells either untreated or treated with BuA for 2 h in complete HBSS. 1% agarose containing 10 lg/ml ethidium bromide
and 50 lg/ml of heat-denatured salmon-sperm DNA was plated on glass petri dishes and allowed to solidify at room temperature. Wells were
prepared by suction pressure and equal amounts of protein (500 lg) from control and BuA-treated cytosolic extracts were added and incubated for
12–18 h at 37 C in a humidified chamber. The endonuclease activity (lysis zone) was observed using a UV-transilluminator and photographed. Lane
1, untreated cytosol and lane 2, BuA-treated cytosol. (D) Effect of iodoacetate on BuA-induced endonuclease activity: EAT cells were preincubated
with varying concentrations of iodoacetate (0.25–1.0 mM) for 30 min, followed by 2 h treatment with BuA at 37 C. Cytosolic extracts were prepared
as described in Materials and methods. Equal amounts of protein were loaded in each well and incubated for 12–18 h at 37 C in a humidified
atmosphere. The lysis zone for endonuclease activity was measured after visualizing with a UV-transilluminator. Lanes: 1, untreated cytosol; 2, BuA-
treated cytosol; 3, 250 lM IAA + BuA; 4, 500 lM IAA + BuA; and 5, 1.0 mM IAA + BuA.
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tempt was made to find out whether BuA-induced
DNA degradation is associated with activation of endo-
nuclease-II in EAT cells. As shown in Fig. 3C, when
compared to the endonuclease activity of control cells
where the EAT cells show basal activity, upon BuA-
treatment, cells undergo apoptosis and the activation
of endonuclease was clearly evident. Fig. 3D shows the
inhibitor analysis of endonuclease-II, and it is obvious
that preincubation of iodoacetate, an inhibitor of endo-
nuclease-II [38,39], inhibited endonuclease-II activity in
a concentration-dependent manner in BuA-treated EAT
cells, suggesting the activation of endonuclease-II uponBuA-treatment. Together, the data obtained indicate
that the apoptotic pathway in EAT cells induced by
BuA requires both activation of CAD and endonucle-
ase-II for DNA fragmentation.
BuA inhibits VEGF production in EAT cells
Since BuA inhibited ascites secretion in vivo, its effect
onVEGF secretion was also studied. Ascites were collect-
ed from control as well as BuA-treated mice for a periods
of 12 days and ELISA studies were performed. The data
obtained from ELISA studies indicated that BuA has a
dose-dependent effect on secretion ofVEGFunder in vivo
Fig. 4. Effect of BuA on in vivo production of VEGF. EAT bearing
mice were injected with 100 lM (300 ll) BuA every alternate day and
the ascites volume was collected after sacrificing the animal. The
production of VEGF in EAT cells was quantitated up to the 12th day
of the EAT cell growth period. ELISA was carried out to quantitate
the VEGF using anti-VEGF165 antibodies.
998 M. Belakavadi et al. / Biochemical and Biophysical Research Communications 335 (2005) 993–1001conditions. Fig. 4 compares the amount of VEGF at dif-
ferent growth period for untreated and BuA-treated EAT
cells. The amount of VEGF increased in untreated EAT
cells over the growth period, whereas the amount of
VEGF in the ascites of BuA-treated EAT cells did not
show any significant increase in synthesis over the same
growth period, suggesting a dose-dependent inhibition
of VEGF secretion upon BuA-treatment in EAT cells.
BuA inhibits tumor-induced neo-vascularization in EAT
cells
In order to provide further evidence for the in vivo
effect of BuA on VEGF production, we looked to ver-
ify its effect on endothelial proliferation in the perito-
neum of EAT-bearing mice. Fig. 5 shows the
comparison between the immunohistochemical staining
of peritoneum sections from control and BuA-treated
EAT cells. H&E staining of peritoneum sections from
the control group appeared well vascularized. In con-
trast, BuA-treated peritoneum sections were character-
ized by a pronounced decrease in vascularity (Fig. 5A),
both in terms of microvascular density (MVD) and the
caliber of the detectable vascular channels. Control
peritoneum sections showed 20 ± 3.3 blood vessels
whereas in case of BuA-treated peritoneum, only
9.1 ± 2.2 blood vessels were observed. Furthermore,
staining for the endothelial-specific marker CD31
showed a striking difference between control and
BuA-treated EAT cells. It is evident that an appreciableamount of endothelial staining (CD31) and infiltrating
tumor cells were observed in control peritoneum sec-
tions (Fig. 5B). In contrast, BuA-treated peritoneum
sections showed a significant reduction in endothelial
staining and tumor infiltration over the experimental
period. These results demonstrate that the apoptotic
effects of BuA on EAT cells could also affect the prolif-
eration of endothelial cells and blood vessel formation
by inhibiting VEGF secretion.Discussion
The short-chain fatty acid BuA is known to induce
apoptosis and differentiation of cancer cells [22]. In addi-
tion,most of the recent studies onBuA suggest that it is an
antiangiogenic agent [23,24]. We have shown previously
that BuA can repress the gene expression of the angiogen-
ic ligand VEGF and its receptorKDR in vitro [31]. In this
report, we have focused our attention on delineating the
precise molecular mechanism underlying the proapoptot-
ic and antiangiogenic activity of BuA in vivo in EAT cells.
We demonstrate an inhibition of proliferation of EAT
cell growth in vivowith a corresponding reduction in asci-
tes volume and cell number upon BuA-treatment. Several
studies have shown thatBuAcan induce apoptosis in vari-
ety of transformed cell types [18,19]. Consistent with
other studies, our results show that there is an induction
of apoptosis in EAT cells upon BuA-treatment. The mor-
phological features of apoptosis such as nuclear conden-
sation and fragmentation of genomic DNA were clearly
indicative in BuA-treated EAT cells. Caspase proteases
play a crucial role in inducing apoptosis, and BuA has
been shown to induce the activation of caspases during
apoptosis [20,21]. Our studies demonstrate that Ac-
DEVD-CHO, a specific caspase-3 inhibitor, completely
inhibited BuA-induced apoptosis, suggesting that BuA-
induced apoptosis in EAT cells is mediated via the cas-
pase-3 pathway. Activation of caspase-3 has been shown
to act on downstream targets such as the DNA-repair en-
zyme poly (ADP-ribose) polymerase (PARP) or DNA
fragmentation factor (DEF), leading to the breaking of
DNA strands into 180 bp pieces [20,41]. It is evident from
our results that BuA can activate CAD, which is associat-
ed with its inhibitor ICAD in the cytosol [42]. Several
studies have shown that activation of endonuclease II is
required forDNA fragmentation and degradation during
cell death [35–37,43]. Our results clearly demonstrate that
activation of endonuclease-II upon BuA-treatment,
which supports our view that BuA could activate both
CAD and DNase-II for complete DNA degradation in
EAT cells, and thus suggest that apoptotic pathway in-
duced by BuA in EAT cells is at least in part mediated
by the activation of CAD and DNase-II.
In parallel observation, the proapoptotic action of
BuA on EAT cells reflects on decreased levels of secretion
Fig. 5. Immunohistochemical studies of EAT bearing mouse peritoneum. (A) H&E staining of peritoneum sections of the EAT bearing mice either
untreated or treated with BuA in vivo. The arrows indicate the blood vessels in the peritoneum. (B) CD31 staining of control and BuA-treated EAT
bearing mouse peritoneum. Sections from the peritoneum that were either untreated or BuA-treated were incubated with anti-CD31 antibodies
overnight at 4 C and stained with ABC-reagent according to the manufacturers protocol. The arrows indicate the presence of endothelial cell lining
and infiltrating tumor cells in the peritoneum of the mouse.
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fect of BuA on endothelial cells has been shown to act
on COX-2 expression [30]. Similarly, studies have also
shown to inhibit the translocation of HIF-1a transcrip-
tion in response to BuA-treatment [32]. We and others
have previously shown the direct effect of BuA on VEGF
and its receptors [31,28,29]. Consistent with the previous
reports, our data demonstrate a dose-dependent inhibi-
tion of VEGF secretion in vivo. The in vivo effect of
BuA on proliferation of endothelial cells is especially vis-
ible when observing blood vessel formation in the perito-
neum of mice. The immunohistological studies clearly
show the inhibition of blood vessel formation in H&E
staining and CD31 analysis, and thus suggest that BuA
primarily acts on endothelial cells, and hence inhibition
of angiogenesis. The biphasic effect of BuA as proapop-
totic and antiangiogenic compound is consistent with
those of some other anticancer drugs [43,44] such as cyclo-
phosphamide [45], and campothecin [46,47], thus stronglysuggesting that these kinds of anti-tumor compounds
seem to be more promising in clinical practice than the
compounds that directly target angiogenesis.
In summary, the data presented here provide evi-
dence that BuA could act as both proapoptotic as well
as an antiangiogenic agent in EAT cells. The multiple
beneficial effects of BuA on EAT cell growth indicate
that this model system would be valuable for use in
developing alternative therapeutic approaches in the
treatment of human ascites tumor malignancies.Acknowledgments
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